 Doses will be titrated over a one-week period until reaching maximum tolerated dose MTD for each participant The MTD will be self administered for three weeks thereafter. Participants demonstrating response to treatment will continue self administering daily PTL201 treatment or placebo, for an additional four weeks. Participants will keep a daily diary. 